by Team Small News | Jan 15, 2026 | Cipla, Lupin, Pharma, Sun Pharma, Zydus
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in...
by Team Small News | Jan 13, 2026 | Pharma, Zydus
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a...
by Team Small News | Jan 12, 2026 | Pharma, Zydus
The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a...
by Team Small News | Dec 20, 2025 | Pharma, Zydus
Zydus Lifesciences Limited, a global life sciences company, has partnered with US-based Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India. The exclusive agreement allows Zydus to offer Myriad’s MyRisk...
by Team Small News | Dec 19, 2025 | Pharma, Zydus
Zydus Lifesciences Limited is a global life sciences company based in India that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare therapies. The company operates in the business of integrated pharmaceutical...
by Team Small News | Dec 11, 2025 | Pharma, Zydus
A 45-year-old businessman, Himanshu Dineshbhai Shah, has filed a complaint with the Vastrapur police alleging that he was assaulted by an unidentified Activa rider and traffic police personnel during a roadside altercation near the Zydus Bridge last month. The...